MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vivani Medical

Fechado

1.01 1

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.98

Máximo

1.01

Indicadores-chave

By Trading Economics

Funcionários

36

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+292.16% upside

Dividendos

By Dow Jones

Próximos Ganhos

9 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

61M

Abertura anterior

0.01

Fecho anterior

1.01

Vivani Medical Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

13 de jun. de 2024, 15:28 UTC

Grandes Movimentos do Mercado

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Comparação entre Pares

Variação de preço

Vivani Medical Previsão

Preço-alvo

By TipRanks

292.16% parte superior

Previsão para 12 meses

Média 4 USD  292.16%

Máximo 4 USD

Mínimo 4 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Vivani Medical - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Informação Financeira

$

Sobre Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.